Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 1.00 |
| ▸ | MGLL | Q99685 | 1/20 | 0.75 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | ARG2 | P78540 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.46 |
| ▸ | TNKS | O95271 | 1/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Styrylboronic Acid SCHEMBL4168786 | 1.00 | CA1 (1.00) | CA1MGLLMAOBCA2ARG2 | |
| Styrylboronic Acid SCHEMBL144461 | 1.00 | CA1 (1.00) | CA1MGLLMAOBCA2ARG2 | |
| Styrylboronic Acid SCHEMBL4390084 | 0.97 | CA1 (0.95) | CA1MGLLMAOBCA2ARG2 | |
| Styrylboronic Acid SCHEMBL28579652 | 0.87 | CA1 (0.76) | CA1MGLLMAOBCA2ARG2 | |
| SCHEMBL2910475 | 0.86 | CA1 (1.00) | CA1MGLLMAOBCA2ARG2 | |
| SCHEMBL12260418 | 0.86 | CA1 (1.00) | CA1MGLLMAOBCA2ARG2 | |
| SCHEMBL8011423 | 0.84 | CA1 (0.73) | CA1MGLLMAOBALDH1A1LMNA | |
| (Z)-1,2-Diphenylethene SCHEMBL29134000 | 0.76 | MAOB (0.69) | CA1MAOBALDH1A1LMNAHDAC3 | |
| SCHEMBL23044739 | 0.75 | CA1 (0.61) | CA1MGLLMAOBCA2MAPT | |
| SCHEMBL13204210 | 0.75 | CA1 (0.61) | CA1MGLLCA2TRPA1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1656 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119060408-A | Boron-containing graphene oxide and flexible silicon rubber-boron-containing graphene oxide neutron shielding material and preparation method thereof | 北京化工大学 | 2024-12-03 | — | — | CN | claimed |
| CN-116655459-A | Synthetic method for selectively synthesizing 4-aryl-2-hexanone | 河南大学 | 2023-08-29 | — | — | CN | claimed |
| CN-112479959-A | Synthesis method of diselenide compound | 温州大学 | 2021-03-12 | — | — | CN | claimed |
| US-10266325-B2 | Polymer with blue light absorbing units chemically bonded to a polymeric backbone of the polymer | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2019-04-23 | — | — | US | claimed |
| US-20180362493-A1 | DINAPHTHOTHIOPHENE COMPOUNDS | SAINT LOUIS UNIVERSITY (US) | 2018-12-20 | — | — | US | claimed |
| US-20170351015-A1 | POLYMER WITH BLUE LIGHT ABSORBING UNITS CHEMICALLY BONDED TO A POLYMERIC BACKBONE OF THE POLYMER | INTERNATIONAL BUSINESS MACHINES CORPORATION | 2017-12-07 | — | — | US | claimed |
| US-9518012-B2 | Method of preparing core-shell copper nanoparticles immobilized on activated carbon and method of preparing chalcogenide compound using nanoparticles as catalyst | PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION (KR) | 2016-12-13 | — | — | US | claimed |
| US-20160311768-A1 | METHOD OF PREPARING CORE-SHELL COPPER NANOPARTICLES IMMOBILIZED ON ACTIVATED CARBON AND METHOD OF PREPARING CHALCOGENIDE COMPOUND USING NANOPARTICLES AS CATALYST | PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION (KR) | 2016-10-27 | — | — | US | claimed |
| US-8361484-B2 | Polymer systems for lung volume reduction therapy | AERIS THERAPEUTICS, INC. (US) | 2013-01-29 | — | — | US | claimed |
| EP-2485678-A1 | COFERONS AND METHODS OF MAKING AND USING THEM | Cornell University (US) | 2012-08-15 | — | — | EP | claimed |
| WO-2011043817-A1 | COFERONS AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY (US) | 2011-04-14 | — | — | WO | claimed |
| US-20100040538-A1 | Polymer Systems for Lung Volume Reduction Therapy | CANADIAN IMPERIAL BANK OF COMMERCE (CA) | 2010-02-18 | — | — | US | claimed |
| EP-2059227-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | Aeris Therapeutics, Inc. (US) | 2009-05-20 | — | — | EP | claimed |
| WO-2008039827-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | AERIS THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | claimed |
| US-20020045775-A1 | Heterogeneously catalyzed process for cross coupling alkenyl halides with boronic acids | MERCK & CO., INC. | 2002-04-18 | — | — | US | claimed |
| US-12637436-B2 | Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2026-05-26 | — | — | US | disclosed |
| EP-4743447-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER AND METABOLIC DISEASES | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2026-05-20 | — | — | EP | disclosed |
| US-5030744-A | Polyborosilazane and process for producing same | TONEN CORPORATION (JP) | 1991-07-09 | — | — | US | disclosed |
| EP-0404503-A1 | Boron-containing, silicon nitride-based ceramic shaped body production process | Tonen Corporation (JP) | 1990-12-27 | — | — | EP | disclosed |
| EP-0389084-A2 | Process for producing a polyborosilazane | Tonen Corporation (JP) | 1990-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311768-A1 | METHOD OF PREPARING CORE-SHELL COPPER NANOPARTICLES IMMOBILIZED ON ACTIVATED CARBON AND METHOD OF PREPARING CHALCOGENIDE COMPOUND USING NANOPARTICLES AS CATALYST | CTRC, AOC2, AOC3 | CA1 612/4885MGLL 3078/4885MAOB 939/4885 |
| US-20100040538-A1 | Polymer Systems for Lung Volume Reduction Therapy | GFER, MUC1, CTH | CA1 1918/4885MGLL 2208/4885MAOB 2732/4885 |
| US-20020045775-A1 | Heterogeneously catalyzed process for cross coupling alkenyl halides with boronic acids | BRPF1, BRD2, BRD7 | CA1 3852/4885MGLL 626/4885MAOB 256/4885 |
| US-20180362493-A1 | DINAPHTHOTHIOPHENE COMPOUNDS | DDT, DNTT, GNPAT | CA1 3582/4885MGLL 3674/4885MAOB 353/4885 |
| US-12637436-B2 | Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof | GRM3, GRM2, GRM1 | CA1 2469/4885MGLL 1431/4885MAOB 3351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.